Why AbbVie's ABBV Drug Setback Creates A Prime Buy-The-Dip Moment

AbbVie Inc. (ABBV) shares took a hit today after disappointing results from its schizophrenia drug trials. However, this setback presents a unique buying opportunity for investors. The company has a strong track record of successful drug development, and this setback is likely to be temporary. Invest in AbbVie stock now to capitalize on the potential rebound. For more accurate predictions on the movement of AbbVie shares, consult the professionals at Stocks Prognosis.